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Background: Lipid nanoemulsions that bind to low-density lipoprotein receptors can   concentrate 
chemotherapeutic agents in tissues with low-density lipoprotein receptor   overexpression and 
decrease the toxicity of the treatment. The aim of this study was to develop a new formulation 
using a lipophilic derivative of methotrexate, ie, didodecyl methotrexate (ddMTX), associated 
with a lipid nanoemulsion (ddMTX-LDE).
Methods: ddMTX was synthesized by an esterification reaction between methotrexate and 
dodecyl bromide. The lipid nanoemulsion was prepared by four hours of ultrasonication of a 
mixture of phosphatidylcholine, triolein, and cholesteryloleate. Association of ddMTX with the 
lipid nanoemulsion was performed by additional cosonication of ddMTX with the previously 
prepared lipid nanoemulsion. Formulation stability was evaluated, and cell uptake, cytotoxicity, 
and acute animal toxicity studies were performed.
Results: The yield of ddMTX incorporation was 98% and the particle size of LDE-ddMTX was 
60 nm. After 48 hours of incubation with plasma, approximately 28% ddMTX was released from 
the lipid nanoemulsion. The formulation remained stable for at least 45 days at 4°C.   Cytotoxicity 
of LDE-ddMTX against K562 and HL60 neoplastic cells was higher than for methotrexate (50% 
inhibitory concentration [IC50] 1.6 versus 18.2 mM and 0.2 versus 26 mM, respectively), and 
cellular uptake of LDE-ddMTX was 90-fold higher than that of methotrexate in K562 cells and 
75-fold in HL60 cells. Toxicity of LDE-ddMTX, administered at escalating doses, was higher 
than for methotrexate (LD50 115 mg/kg versus 470 mg/kg; maximum tolerated dose 47 mg/kg 
versus 94 mg/kg) in mice. However, the hematological toxicity of LDE-ddMTX was lower 
than for methotrexate.
Conclusion: LDE-ddMTX was stable, and uptake of the formulation by neoplastic cells was 
remarkably greater than of methotrexate, which resulted in markedly greater cytotoxicity. 
LDE-ddMTX is thus a promising formulation to be tested in future animal models of cancer or 
rheumatic disease, wherein methotrexate is widely used.
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Introduction
Methotrexate (2,4-diamino,N10-methylpteroyl glutamic acid) is an antiproliferative 
and immunosuppressive agent widely used against a broad spectrum of diseases. 
Methotrexate is a potent inhibitor of dihydrofolate reductase, and can also inhibit 
thymidylate synthase and 5-aminoimidazole carboxamide ribotide transformylase. 
These enzymes are involved in the synthesis of thymidylate, purines, methionine, 
and serine.1 Methotrexate was introduced in the 1940s, and is still used extensively 
in clinical practice. Methotrexate has relatively low toxicity compared with other 
chemotherapeutic agents,2 but is not devoid of side effects, including nephrotoxicity, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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hepatotoxicity, myelotoxicity, interstitial pneumonitis, and 
chronic interstitial obstructive pulmonary disease.3
The effectiveness of methotrexate is often hampered by 
development of drug resistance mechanisms, such as inhibi-
tion of active transport involving the cell folate receptor that 
mostly internalizes methotrexate, and is hydrophilic and poorly 
diffused through cell membranes. Aiming to bypass drug resis-
tance and yet retain cytotoxic activity, several strategies have 
been attempted. One of these strategies consists of chemical 
modification of methotrexate to improve lipophilicity. In this 
regard, the γ-carbonyl position is preferentially targeted to 
attach lipophilic groups to the methotrexate molecule, and in 
fact modification at the γ and, to a lesser extent, the α-carbonyl 
position did not decrease the drug cytotoxicity.4 Drug delivery 
systems have also been used to improve cytotoxicity and reduce 
toxicity, such as loading of methotrexate into liposomes,4,5 
dendrimers,6 micelles,7 chitosan polymers,8 and tuftsin-like 
peptide carriers,9 as well as attachment to polymeric chains. 
Other formulations have been described, such as chylomicron-
like emulsions, for oral use.10 The use of a solid lipid nanopar-
ticle system as a methotrexate carrier was reportedly shown 
to improve drug pharmacokinetics and to achieve regression 
of Ehrlich ascites carcinoma in mice.11,12
The demonstration by Ho et al13 that low-density lipopro-
tein receptors are overexpressed in neoplastic cells, paved 
the way for the use of lipoproteins14–17 and subsequently of 
lipoprotein-like nanoemulsions18,19 as vehicles to concentrate 
chemotherapeutic agents in neoplastic tissues. Taking this 
approach, the low-density lipoprotein receptor-mediated 
endocytic pathway is used to internalize drug-loaded lipid 
particles.14–17 We showed that cholesterol-rich nanoemulsions, 
with a lipid structure mimicking low-density lipoprotein, has 
the ability to bind to low-density lipoprotein receptors. A lipid 
nanoemulsion is made without protein but, in contact with 
plasma, acquires apolipoprotein E, which is recognized by 
low-density lipoprotein receptors.19,20 In preclinical studies 
using chemotherapeutic agents, such as carmustine21 and 
lipophilic derivatives of paclitaxel22 and etoposide,23,24 the 
toxicity of these agents was markedly reduced by associa-
tion with a lipid nanoemulsion, while the pharmacological 
action was maintained or even increased. In clinical studies 
enrolling patients with breast and ovary cancer, the amount 
of lipid nanoemulsion accumulated in tumor tissue was 
markedly greater than in normal tissue.25–28 In clinical trials 
enrolling patients with advanced solid tumors and hemato-
logical neoplasias,21,29 we showed that the toxicity of high-
dose preparations of carmustine, paclitaxel, and etoposide 
associated with a lipid nanoemulsion was minimal.
This study aimed to investigate whether the association of 
methotrexate and a lipid nanoemulsion could increase neo-
plastic cell uptake and cytotoxicity, and decrease the toxicity 
of the drug. To improve the association yield and stability 
of the formulation, two dodecyl groups were attached to the 
methotrexate molecule.
Methods
Materials
Methotrexate (Miantrex®) was purchased from Pfizer (Bentley, 
Australia); triolein, cholesteryloleate, cholesterol, phosphati-
dylcholine, dimethyl sulfoxide, and cesium carbonate from 
Sigma (St Louis, MO); methanol and acetonitrile from Merck 
  (Darmstadt, Germany); and methotrexate sodium salt from Deg 
Importacao De Produtos Quimicos Ltd (São Paulo, Brazil).
Nuclear magnetic resonance (NMR) of 1H and 13C used 
to characterize the ddMTX structure was performed using a 
Bruker DPX-300 instrument (Brucker, Karlsruhe, Germany). 
Purity was analyzed by high-performance liquid chromatogra-
phy in a Shimadzu SPD-10 AV column (Shimadzu,   Columbia, 
ML). The structure of the ddMTX was also   confirmed by 
mass spectrometry using a Q-TOF Ultima (Micromass, 
Manchester, UK) and elemental analysis using a Perkin Elmer 
CHN 2400 elemental analyzer (Perkin Elmer, Sciex, Shelton, 
CT). Transmission electron microscopy imaging of LDE-
MTX was performed using a LEO 906E transmission electron 
microscope (Zeiss, Oberkochen, Germany) at 100 kV .
Isogenic female BALB/c mice (±20 g, aged 30–45 days) 
were supplied by the Butantan Institute (São Paulo, Brazil). 
All animals used in this study were housed in a temperature-
controlled room, with a 12-hour light/dark cycle, and food 
and water available ad libitum. The ethics committee of 
University of Sao Paulo Medical School Hospital approved 
all the animal experiments.
synthesis of ddMTX
Briefly, ddMTX was synthesized following the method 
described by Rosowsky et al.30 Methotrexate sodium salt 
(2.0 g, 4.1 mmol) was diluted in 120 mL of   dimethylsulfoxide, 
and over it were added cesium carbonate (1.43 g, 
4.40 mmol) and dodecyl bromide (2.5 g, 10 mmol). The 
mixture was stirred for 24 hours at room temperature, and 
100 mL of water was added to quench the reaction. The prod-
uct was extracted with chloroform (5 × 50 mL). The organic 
phase was washed with a saturated sodium chloride solu-
tion (3 × 100 mL), dried with magnesium sulfate, filtered, 
and   concentrated. The product was purified by liquid 
  chromatography using silica gel (230–400 mesh) with International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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methanol/chloroform, from 2.5% to 100% of methanol. 
Pf 122°C–124°C. Yield was 98%.
1H δ (ppm): 0,86 (6H, t, J = 6.0 Hz), 1.23 (36H, s); 
1.50–1.68 (4H, m), 2.08–2.20 (1H, m), 2.21–2.32 (2H, m), 
2.42–2.50 (1H, m), 3.12 (3H, s), 4.00 (2H, t, J = 6.0 Hz), 4.13 
(2H, t, J = 6.0 Hz), 4.67 (2H, s), 4.75–4.83 (1H, m), 5.98 
(2H, bs), 6.69 (2H, d, J = 6.0 Hz); 7,02 (1H, bs), 7.69 (1H, d, 
J = 6.0 Hz), 8.56 (1H, s).13C δ (ppm): 13.99, 22.54, 25.75, 
27.31, 28.42, 29.15, 29.24, 29.53, 30.55, 31.80, 38.90, 52.16, 
55.68, 64.85, 65.66, 111.21, 121.37, 121.87, 128.79, 146.65, 
146.71, 149.10, 151.31, 154.86, 162.51, 162.89, 166.96, 
172.63, 173.21. Mass: 338.31, 381.27, 675.63, 791.48 (100), 
792.49, 793.52. IV ν (cm−1): 3478.8, 2924.2, 2855.9, 1737.5, 
1630.7, 1512.6, 1445.9, 1204.3, 1096.0, 816.9. Elemental 
analysis: Calc: 66.80 (C), 8.92 (H), 14.16 (N). Expt: 66.50 
(C), 8.68 (H), 14.10 (N).
high-pressure liquid  
chromatography measurements
A high-pressure liquid chromatographic column equipped 
with an ultraviolet detector at 300 nm was used to analyze 
and quantify methotrexate and ddMTX. Chromatographic 
separation was achieved with a ShimPack C18 (2) 5 µm 
(15 cm × 6 mm) analytical column (Phenomenex, Torrance, 
CA) protected by a Luna C18 (2) guard cartridge. The mobile 
phase was methanol at a flow rate of 1.0 mL/minute for 
ddMTX and buffer of sodium acetate:acetonitrile (90:10) 
for methotrexate. For quantification of both compounds, 
a calibration curve was constructed at concentration ranging 
from 78.12 ng to 50,000 ng.
Distribution coefficient
The distribution coefficient is the log distribution coefficient at 
a particular pH. Log D at pH 7.4 is often quoted to give an indi-
cation of the lipophilicity of a drug at the pH of blood plasma. 
In aqueous/organic systems, the organic phase   concentration 
is, by convention, the numerator, and the aqueous phase 
concentration is the denominator. 1.0 mL of n-octanol 
and 1.0 mL of sodium phosphate buffer, pH 7.4 were added to 
1 mg of ddMTX. The mixture was gently shaken for 24 hours 
at 37°C. The amount of drug in each phase was quantified 
by high-pressure liquid chromatography.
Preparation of lipid nanoemulsion  
and LDe-ddMTX
In brief, the lipid nanoemulsion was prepared from a lipid 
mixture composed of 40 mg cholesteryloleate, 20 mg egg 
phosphatidylcholine, 1 mg triolein, and 0.5 mg cholesterol. 
Emulsification of lipids by prolonged ultrasonic irradiation 
in aqueous media and the procedure of two-step ultracen-
trifugation of the crude emulsion with density adjustment by 
addition of KBr to obtain a lipid nanoemulsion were carried 
out as described previously.20 The lipid nanoemulsion was 
dialyzed against Tris solution (pH 8.05) and passed through 
a 0.22 µm filter for the experiments.
ddMTX 6 mg was incorporated into the lipid nano-
emulsion (1 mL, 30 mg of total lipids) by solubilization of 
ddMTX in ethanol (10% v:v) and adding it into the emul-
sion. The solution was then sonicated for one hour at 70°C 
using a Branson Sonifier 450 (Danbury, CT), equipped with 
a 1 cm flat titanium probe. LDE-ddMTX was centrifuged at 
3500 rpm for 15 minutes to separate the LDE-ddMTX from 
the free form of the drug that precipitated to the bottom of 
the tube. LDE-ddMTX was then passed through a 0.22 µm 
pore polycarbonate filter and kept at 4°C until it was used. 
The yield of each batch was assayed before use. For quanti-
fication of ddMTX-loaded LDE, 10 µL LDE-ddMTX were 
dissolved in 1.0 mL of methanol to break the formulation. 
The ddMTX mass contained in the lipid nanoemulsion was 
measured in 20 µL of the previous solution using a calibra-
tion curve. The amount of drug associated to the lipid nano-
emulsion was always measured by high-performance liquid 
  chromatography before the experiments.
LDe-ddMTX particle size
The average size of the LDE-ddMTX particles was measured 
using a zeta potential analyzer (Brookhaven Instruments 
Corporation, Holtsville, NY) at 25°C. All the samples were 
kept at 4°C and diluted and filtrated immediately prior to 
diameter measurement. In order to evaluate the stability of the 
formulation, the mean diameters of the lipid nanoemulsion 
and LDE-ddMTX particles were measured over 45 days.
Transmission electron microscopy  
of LDe-ddMTX
Five microliters of LDE-ddMTX at approximately 0.2 mg/mL 
were applied on parlodium-carbon-coated copper grids of 300 
or 400 meshes. After 1–2 minutes, the excess liquid is blotted 
with tissue paper, leaving a small amount of residual fluid. 
Negative staining was done with a 5 µL drop of 2% ammonium 
molybdate pH 7.2 for 5–10 seconds and then blotted dry. Grids 
were examined under a LEO 906E transmission electron 
microscope (Zeiss, Oberkochen, Germany) at 100 kV accel-
eration voltage. Images were acquired by a   charge-coupled 
device camera (MegaView III) through the universal 
  transmission electron microscope imaging platform program International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(Olympus Soft Imaging Solutions GMBh, Oberkochen, 
  Germany), and saved in TIF extension.
In vitro release of ddMTX from lipid 
nanoemulsion
LDE-ddMTX was dialyzed against human plasma to evaluate 
drug release from the lipid nanoemulsion. The dialysis bags 
(Seamless cellulose tubing, Sigma) were soaked in deionized 
water before placing 1.0 mL of LDE-ddMTX into the bag. 
The bags were placed into a tube containing 20 mL of human 
plasma under magnetic stirring for 48 hours at 37°C. Samples 
of 5 µL were collected at 0.5, 1, 2, 3, 4, 5, 6, 20, 24, 48 and 
72 hours and analyzed using high-performance liquid chroma-
tography for content mass of ddMTX in the nanoemulsion.
cytotoxic activity assays
Human erythroleukemia cells (K562) and human promy-
elocytic leukemia cells (HL60) were cultured in RPMI 
1640 medium supplemented with streptomycin 50 µg/mL, 
penicillin 50 IU/mL, and 10% (v/v) fetal calf serum (all from 
Invitrogen, Carlsbad, CA). Cells were maintained at 37°C, 
5% CO2, and 100% relative humidity, and subcultivated 
2–3 times a week, with 0.4% Trypan blue staining to assess 
cell growth and viability.
The starting inoculums of 5 × 105 K562 and HL60 cells/mL 
were seeded in the exponential phase of growth into 96-well 
culture plates (Nunc TM, Roskilde, Denmark) with LDE-
ddMTX (0.05–0.5 mM), methotrexate (2.5–37.5 mM), and 
lipid nanoemulsion, at the same volume as the lipid nano-
emulsion with the associated drug, were added to the cells 
incubated. After 48 hours of incubation, the medium was 
removed and the number of living tumor cells was determined 
by the colorimetric MTT assay.31 Briefly, MTT solution was 
added to each well (1.2 mg/mL) and incubated for 4 hours. 
MTT was reduced by mitochondrial dehydrogenase in the 
viable cells to a purple formazan product, which was dis-
solved in 100 µL dimethyl sulfoxide for measurement of 
absorbance at 570–655 nm in an enzyme-linked immuno-
sorbent assay plate reader.
Cell viability of each well was expressed as the survival 
index. The IC50 was determined as the drug concentration 
required to achieve 50% cell growth inhibition.
LDe-ddMTX uptake by neoplastic cells
HL60 and K562 cell suspensions were seeded in 35 mm Petri 
dishes at 105 × cells/mL and incubated at 37°C, 5% CO2, 
and 100% relative humidity. After 24 hours of cell growth, 
the medium was replaced by fresh medium supplemented 
with 10% lipoprotein-deficient serum, and the cells were 
incubated for 24 hours in the same conditions. The medium 
was replaced by fresh medium supplemented with 10% fetal 
bovine serum, and increasing amounts of methotrexate and 
LDE-ddMTX were added at final drug concentrations ranging 
from 0.15 to 2.0 mM. After 4 hours of incubation at 37°C, the 
cells were washed three times with cold phosphate-buffered 
saline, centrifuged at 1500 rpm for 3 minutes, and then lysed 
in 1.0 mL of phosphate-buffered saline using a Branson 
Sonifier 450 sonicator for 10 seconds. Protein precipitation 
was performed with the addition of 500 µL 50:50 isopropyl 
alcohol to ethyl acetate and acetonitrile for ddMTX and 
methotrexate, respectively. The samples were mixed for one 
minute and centrifuged at 13000 rpm for 10 minutes, and 
the supernatant was dried under nitrogen flow. Methanol 
and buffer of sodium acetate:acetonitrile (90:10) were used 
for ddMTX and methotrexate, respectively, as the mobile 
phase after extracting the drugs using Stracta cartridges 
(Phenomenex). The organic phase was concentrated and 
reconstituted in 0.2 mL of methanol and quantified by high-
performance liquid chromatography. The Lowry protein 
quantification method was used to correct drug/mg of protein 
concentrations.32
Maximum tolerated dose and 50% lethal 
dose of LDe-ddMTX
Groups of 10 mice were intravenously injected via the retro-
orbital sinus, following a dose-escalation schedule based 
on three dose levels of methotrexate and LDE-ddMTX 
(47, 94, and 180 mg/kg). The studies were performed in 
two schedules, ie, a single-dose and a three-day multiple-
dose schedule. Lipid nanoemulsion and saline control were 
administered. Animals were observed until day 7 and body 
weight measurements were performed every 2 days. The 
maximum tolerated dose (defined as the dose that resulted in 
approximately 15% loss in body weight and does not cause 
lethality). The lethal dose of 50% (LD50) was defined as the 
administered dose which caused death of 50% of the animals, 
calculated by interpolation of results (death percentage in 
the group/dose).
hematological toxicity
Blood samples were collected 24 hours after injection of a 
single 180 mg/kg dose of LDE-ddMTX and methotrexate by 
retro-orbital sinus puncture, using heparinized   Helmington 
microcapillary tubes. Hematology parameters included 
  erythrocyte, leukocyte, leukocyte differential count, and 
platelets were performed using a hemocytometer (Optik International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Labor, Friedrichshafen, Germany). Briefly, blood was 
1/1000 diluted in saline for erythrocyte count, 1/100 in 
Becker reagent for platelets, and 10 µL was added to the 
hemocytometer. For leukocytes, blood was 1/100 diluted in 
Turk reagent, and an aliquot of nondiluted blood was used 
on a glass slide for leukocyte differential count. Slides were 
stained using a Panoptic kit (Laborclin, Parana, Brazil). 
Erythrocytes and leukocytes were determined by counting 
the cells in the large squares, and platelets were counted in 
the central squares of the hemocytometer.
statistical analysis
Cell uptake and IC50 data were expressed as the mean ± stan-
dard error of the mean, and were analyzed by the nonparamet-
ric t-test. Kaplan–Meier analysis was used to assess survival 
in the different treatment groups. Maximum tolerated dose, 
LD50, and hematological profile values were also expressed 
as the mean ± standard error of the mean, and were analyzed 
by analysis of variance followed by Bonferroni’s test. In all 
analyses, differences of 0.05 or less were considered to be 
statistically significant.
Results
synthesis of LDe-ddMTX
The methotrexate derivative, ddMTX, was obtained by 
esterification of the α- and γ-carbonyl groups of the glutamic 
acid residue in the presence of cesium carbonate and dodecyl 
bromide (Figure 1). The ddMTX structure was confirmed 
by 1H and 13C NMR, in which characteristic peaks corre-
sponding to the dodecyl group were present. Esterification 
achieved a 98% yield and a high purity rate, as confirmed 
by high-performance liquid chromatography analysis. Mass 
spectrometry showed a signal 791.48 m/z corresponding to 
the molecular weight of the derivative. Those results were 
corroborated by the elemental analysis.
The esterification reaction markedly enhanced the metho-
trexate distribution coefficient, which was −1.4 before and 
3.9 after the reaction. These data confirmed successful and 
optimized association with the lipid nanoemulsion, which 
attained a 98% association rate.
As analyzed by laser light scattering, the average par-
ticle size of the lipid nanoemulsion without ddMTX was 
approximately 40 nm and that of the lipid nanoemulsion with 
ddMTX was approximately 60 nm. Transmission electron 
microscopy showed particles of quasispherical shape, with 
diameters in the same range as those measured by laser light 
scattering (Figure 2).
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ddMTX.
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stability of LDe-ddMTX
During the process of association of the drug with the lipid 
nanoemulsion, which comprised an ultrasonication step, there 
was no structural modification of the drug, a finding that was 
subsequently confirmed after 45 days of storage at 4°C. On 
the other hand, the average size of LDE-ddMTX increased 
from 60 nm to 70 nm. The rate of dissociation of ddMTX 
from the lipid nanoemulsion was 10% ± 5%, as observed at 
4°C storage for 45 days. The ddMTX that dissociated from 
the lipid nanoemulsion was macroscopically observed by the 
appearance of a yellow powder of ddMTX at the bottom of 
the flask. The stability of the LDE-ddMTX association was 
analyzed over 48 hours of dialysis against human plasma. 
Free ddMTX was released from the dialysis bag at a slow 
rate of 28%, and most of the dissociation occurred in the first 
24 hours of the dialysis period (Figure 3).
In vitro studies
The cytotoxicity of LDE-ddMTX was markedly higher than 
that of methotrexate. For K562 cells, the cytotoxicity of the 
new formulation was approximately 10-fold higher and for 
HL60 was 100-fold higher than for methotrexate (Figure 4, 
see Table 1). Incubation of HL60 and K562 with the lipid 
nanoemulsion alone did not inhibit cell growth. It is worth-
while to point out that the cytotoxicity of free unassociated 
ddMTX was not tested because of its high lipophilicity that 
does not favor appropriate conditions for incubation with 
cells. For this purpose, it would be necessary to use organic 
solvents that would be toxic to the cells.
The IC50 for K562 cells incubated with LDE-ddMTX was 
1.6 mM, whereas the IC50 for cells incubated with methotrex-
ate was 18.2 mM (P , 0.0001). For the HL60 cells, the IC50 
was 0.2 mM for incubation with LDE-ddMTX and 26 mM 
for incubation with methotrexate (P = 0.0002).
Figure 5 shows the uptake of LDE-ddMTX and metho-
trexate by K562 and HL60 cells 4 hours after incubation with 
increasing amounts of both preparations. The uptake amount 
refers to the nonmetabolized methotrexate and ddMTX found 
within the cells. It is notable that the uptake of LDE-ddMTX 
by K562 cells was 90-fold higher than that of methotrexate 
(P , 0.0001) while the uptake by HL60 was 75-fold higher 
(P , 0.0001).
In vivo toxicity
The toxicity of both LDE-ddMTX and methotrexate to mice 
was tested in two escalating dose schedules, namely single-
dose and multiple-dose schedules. Using the single-dose 
schedule, the tolerability of methotrexate was greater than 
that of LDE-ddMTX, as evaluated by smaller weight loss 
and greater survival, despite the hematological toxicity of 
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Table  1  Ic50  values  of  methotrexate,  ranging  from  2.25  to 
22.5 mM and of LDe-dMTX, ranging from 0.1 to 2 mM in K562 
and hL60 cell lines. cells were incubated for 48 hours at 37°c
Formulations IC50 (mM)
K562 HL60
LDe-ddMTX 1.6 0.2
MTX 18.2 26
Abbreviations: ddMTX, didodecyl methotrexate; MTX, methotrexate; LDe, lipid 
nanoemulsion; Ic50, 50% inhibitory concentration.
LDE-ddMTX being lesser than that elicited by methotrexate 
(Figure 6). In the multiple-dose scheme, with both LDE-
ddMTX and methotrexate treatments, all the animals died 
by the end of 7 days of observation. As shown in Table 2, 
both the MTD and the LD50 were higher for methotrexate 
than for LDE-ddMTX.
Discussion
The major achievement in this study was the manufacture of 
a formulation for methotrexate endowed with an ability to 
concentrate the drug into the cell at much greater rates than 
those of commercial methotrexate.
The excellent approximately 100% yield of the esterifi-
cation reaction and the excellent approximately 100% asso-
ciation of ddMTX with the lipid nanoemulsion support the 
assumption that conditions for the manufacture of the LDE-
ddMTX were near optimal. Esterification is a powerful strat-
egy used in medicinal chemistry to improve drug features, 
such as passive transport, lipophilicity, and reduced toxicity. 
Esterification of both the α- and γ-carbonyl groups used here 
was a practical alternative to regioselective esterification 
of only the γ-carbonyl group, which is often a low-yield 
  reaction. The choice of dodecyl group to attach to metho-
trexate was based on a study by Rosowsky et al30 reporting 
that esters containing 10–12 carbon chains are more suited to 
maintain drug activity than long-chain methotrexate esters. 
The latter are less prone to bind to dihydrofolate reductase, 
which leads to decreased cytotoxicity. The higher 
distribution coefficient (n-octanol/water) showed by International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ddMTX compared with   methotrexate, ie, 3.9 and −1.4, 
respectively, was key to achieving the high entrapment 
  efficiency obtained here.
Thus, both the esterification reaction and the procedure 
for associating the drug with the lipid nanoemulsion involve 
methods that are easy to perform, do not require expensive 
reagents, and can be easily adapted to large-scale produc-
tion conditions. Ultimately, the particles of average size 
60 nm resemble previously obtained preparations of lipid 
nanoemulsion-loaded paclitaxel, carmustine, or etoposide 
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Figure 5 Uptake of LDe-ddMTX (●) and methotrexate (o) 4 hours by (A) K562 and (B) HL60 cell lines. Cells were incubated with the formulations (final concentration 
range 0.15–2.0 mM) for 4 hours at 37°C, lysed, and the drugs were then quantified by high-performance liquid chromatography. Results are presented the mean ± standard 
error of the mean of three experiments.
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derivatives. These previously described formulations 
showed the ability to produce a several-fold reduction in 
the toxicity of the associated chemotherapeutic agents, 
whereas the pharmacological action was preserved or even 
improved.21–23
A precondition for drug targeting is the stability of the 
drug-carrier in the circulation until final uptake by the tar-
geted tissue. In the dialysis experiments, the fact that only 
a small fraction of the ddMTX associated with the lipid 
nanoemulsion was released from the bags over 48 hours 
supports the stability of the complex. A potential limitation 
of this experimental setting is that the interactions between 
plasma proteins and lipoproteins are more restricted, because 
LDE-ddMTX particles are in a solution inside the dialysis 
bag whereas the plasma proteins are outside. Passage of 
proteins through the membrane is difficult due to their size, 
so interactions occur mainly at the membrane pores. ddMTX 
release from the lipid nanoemulsion could also be evaluated 
by mixing LDE-ddMTX with plasma inside the dialysis bag, 
but the drug eventually released from the lipid nanoemulsion 
could bind to plasma proteins or lipoproteins and remain in 
the bag, which would prevent dissociation from the lipid 
nanoemulsion.
LDE-ddMTX was mostly stable for at least 45 days. This 
was indicated by both the constant particle size and preservation 
of the ddMTX chemical structure during the observation period. 
As already mentioned in respect to drug entrapment by the lipid 
nanoemulsion, the increase in the distribution coefficient also 
contributes to the stability of the complex. Coalescence is criti-
cal for the stability of emulsions and other particulate systems.33 
The lipid nanoemulsion is prepared with phosphatidylcholine, 
a positively charged phospholipid that produces more stable 
systems than negatively charged phospholipids.34
The uptake of methotrexate by cells occurs via folate 
receptors. Methotrexate is a substrate for   polyglutamylation 
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Figure 6 (A) red cell count, (B) platelet count, (C) leukocyte count, and (D) leukocyte differential count in mice after 24 hours of intravenous LDe-ddMTX or methotrexate 
(both at 180 mg/kg dose) administration and after intravenous LDe without methotrexate.
Notes: ns indicates p  0.05; *** indicates p , 0.001.
Abbreviations: ddMTX, didodecyl methotrexate; LDe, lipid nanoemulsion; LYMPh, lymphocytes; NeUTrO, neutrophyls; eOsINO, eosinophyls; MONO, monocytes; 
LYMPhOBL, lymphoblast.
Table 2 Maximum tolerated dose and 50% lethal dose values of 
methotrexate and LDe-ddMTX intravenously administered as a 
single dose in BALB/c mice
Formulations Single dose
MTD LD50
LDe-ddMTX 47 mg/kg 115 mg/kg
MTX 94 mg/kg 470 mg/kg
Abbreviations: ddMTX, didodecyl methotrexate; MTX, methotrexate; LDe, lipid 
nanoemulsion; LD50, 50% lethal dose; MTD, maximum tolerated dose.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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performed by folypolyglutamyl synthase that enhances cell 
retention of the drug. The enzyme activity varies among 
tumor cell lines, and it has been suggested that defective 
polyglutamation may partially account for tumor resis-
tance to methotrexate.1 Therefore, it is remarkable that 
the   cellular uptake of LDE-ddMTX was 75-fold higher 
than of methotrexate in HL60 cells and 90-fold higher 
in K562 cells. This finding can be ascribed to either the 
receptor-mediated endocytic pathway being furnished by 
the lipid nanoemulsion drug-carrier or to the lipophilic 
features of ddMTX. The biological activity of lipophilic 
derivatives of methotrexate can be either the result of 
a direct effect on cell enzymes, or being mediated by 
intracellular release of free drug, that will ultimately be 
responsible for the activity.35
The 75-fold greater uptake of LDE-ddMTX than 
methotrexate by HL60 cells was matched by 100-fold 
greater cytotoxicity, whereas the 90-fold greater uptake by 
K562 cells was linked with 10-fold greater cytotoxicity to 
these cells. Our results suggest that uptake of methotrexate 
is an important limitation for cytotoxicity, and when cell 
internalization of the drug increases, the pharmacological 
action of the compound can be optimized. However, it is 
noteworthy that the greatest uptake did not correspond to 
the greatest cytotoxicity, because the cytotoxicity of K562 
was not higher than for HL60. The mechanism of action of 
methotrexate involves inhibition of tetrahydrofolate synthesis 
through its bonding to dihydrofolate reductase, interfering 
with DNA synthesis and repair. The fact that there was no 
cytotoxicity when the lipid nanoemulsion was incubated with 
the two cell lines without methotrexate and demonstrates that 
this vehicle has no toxicity.
In the animal toxicity experiments, the marked differ-
ences created by the association of ddMTX and the lipid 
nanoemulsion were reflected in the fact that escalating doses 
resulted in lower survival rates for LDE-ddMTX compared 
with methotrexate at all dose levels. It is possible that the 
increased toxicity of LDE-ddMTX to animals was consequent 
to the marked increase in cell uptake and in vitro cytotoxicity. 
It is interesting that the hematological toxicity was lower for 
LDE-ddMTX, which suggests an as yet undetermined myelo-
protective mechanism conferred by the lipid nanoemulsion.
The 10–90-fold greater cytotoxicity of LDE-ddMTX, 
which resulted in a four-fold increase in LD50, as estimated 
by animal survival, and a two-fold increase in the maximum 
tolerated dose, suggests that LDE-ddMTX can be used in 
smaller doses, and would still have superior pharmacological 
activity with low toxicity.
As a limitation of this study, it can be mentioned that 
a comparison between methotrexate and ddMTX both 
associated with the lipid nanoemulsion could not be made 
because methotrexate associates poorly with this nanoemul-
sion system.
The lipid nanoemulsion also has the ability to concen-
trate in atherosclerotic lesions, as shown in cholesterol-fed 
rabbits.36 In a subsequent as yet unpublished study, we 
observed that treatment of atherosclerotic rabbits with 
LDE-ddMTX resulted in marked regression of the lesions. 
This finding widens the potential therapeutic applications 
of LDE-ddMTX.
Conclusion
In conclusion, comparing LDE-ddMTX with other metho-
trexate delivery systems described in the literature, such as 
gelatin/methotrexate conjugates,37 polymers,7,8 liposomes,4,5 
dendrimers,6 solid lipid nanoparticles,11,12 and chylomicron-
mimicking carrier emulsions,10 this novel formulation for 
intravenous use, in which the association of ddMTX with 
the vehicle is virtually complete and stable, showed equiva-
lent or superior cytotoxicity. These findings warrant further 
preclinical investigation.
Acknowledgments
This study was supported by a State of Sao Paulo Research 
Foundation grant. Professor Maranhão has a research award 
from the National Council for Scientific and Technological 
Development. The authors are indebted to Sylvia M Car-
neiro for her help with the transmission electron microscopy 
experiments.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Estlin EJ. Continuing therapy for childhood acute lymphoblastic   leukaemia: 
clinical and cellular pharmacology of methotrexate, 6-  mercaptopurine and 
6-thioguanine. Cancer Treat Rev. 2001;27:351–363.
2.  Huennekens FM. The methotrexate story: a paradigm for devel-
opment of cancer chemotherapeutic agents. Adv Enzyme Regul. 
1994;34:397–419.
3.  Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. 
Antineoplastic agents. In: Hardman JG, Limbird LE, Gilman A, editors. 
Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 
10th ed. New York, NY: McGraw-Hill; 2001.
4.  Kaasgaard T, Adresen TL, Jensen SS, Holte HO, Jensen LT, 
Jorgensen K. Liposomes containing alkylated methotrexate analogues 
for   phospholipase A2 mediated tumor targeted drug delivery. Chem Phys 
Lipids. 2009;157:94–103.
5.  Doddoli C, Chez O, Barlési F, et al. In vitro and in vivo methotrexate 
disposition in alveolar macrophages: Comparison of pharmacokinetic 
parameters of two formulations. Int J Pharm. 2005;297:180–189.International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2295
Methotrexate derivative in a lipid nanoemulsion
  6.  Gurdag S, Khandare J, Stapels S, Metherly LH, Kannan RM.   Activity 
of dendrimer-methotrexate conjugates on methotrexate-sensitive 
and -resistant cell lines. Bioconjug Chem. 2006;17:275–283.
  7.  Li Y, Kwon GS. Micelle-like structures of poly(ethylene oxide)-block-
poly(2-hydroxyethyl aspartamide)-methotrexate conjugates. Colloids 
and Surfaces B: Biointerfaces. 1999;16:217–226.
  8.  Seo DH, Jeong YI, Kim DG, Jang MJ, Jang MK, Nah JW. Methotrexate-
incorporated polymeric nanoparticles of methoxypoly(ethyleneglycol)-
grafted chitosan. Colloids Surf B Biointerfaces. 2009;69:157–163.
  9.  Bai KB, Láng O, Orbán E, et al. Design, synthesis, and in vitro   activity 
of novel drug delivery systems containing tuftsin derivatives and 
methotrexate. Bioconjug Chem. 2008;19:2260–2269.
  10.  Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP. Engineered 
  chylomicron mimicking carrier emulsion for lymph targeted oral 
delivery of methotrexate. Int J Pharm. 2009;380:181–188.
  11.  Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on 
characteristics of solid lipid nanoparticles designed for oral lymphatic 
delivery. Nanomedicine. 2009;5:184–191.
  12.  Ruckmani K, Sivakumar M, Ganeshkumar PA. Methotrexate loaded 
solid lipid nanoparticles (SLN) for effective treatment of carcinoma.   
J Nanosci Nanotechnol. 2006;6:2991–2995.
  13.  Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein 
(LDL) receptor activity in human acute myelogenous leukemia cells. 
Blood. 1978;52:1099–1114.
  14.  Masquelier M, Vitols S, Peterson C. Low-density lipoprotein as a carrier 
of antitumoral drugs: in vivo of drug-human low-density lipoproteins 
complexes in mice. Cancer Res. 1986;46:3842–3847.
  15.  Masquelier M, Vitols S, Palsson M, Mars U, Larsson BS, Peterson CO. 
Low density lipoprotein as a carrier of cytostatics in cancer   chemotherapy: 
study of stability of drug-carrier complexes in blood. J Drug Target. 
2000;8:155–164.
  16.  Lundberg B. Preparation of drug-low density lipoprotein complexes for 
delivery of antitumoral drugs via the low density lipoprotein pathway. 
Cancer Res. 1987;47:4105–4108.
  17.  Vitols S, Angelin B, Ericsson SG, et al. Uptake of low density lipopro-
teins by human leukemic cells in vivo: relation to plasma lipoprotein 
levels and possible relevance for selective chemotherapy. Proc Natl 
Acad Sci U S A. 1990;87:2598–2602.
  18.  Maranhão RC, Garicochea B, Silva EL, Llacer PD, Pileggi FJC, 
Chamone DAF. Increased plasma removal of microemulsions resem-
bling the lipid phase of low-density lipoproteins (LDL) in patients with 
acute myeloid leukemia: a possible new strategy for the treatment of 
the disease. Braz J Med Biol Res. 1992;25:1003–1007.
  19.  Maranhão RC, Garicochea B, Silva EL, et al. Plasma kinetics and 
biodistribution of a lipid emulsion resembling low-density lipo-
protein in patients with acute leukemia. Cancer Res. 1994;54: 
4660–4666.
  20.  Maranhão RC, César TB, Pedroso-Mariani SR, Hirata MH, 
Mesquita CH. Metabolic behavior in rats of a non-protein microemul-
sion resembling low density lipoprotein. Lipids. 1993;28:691–696.
  21.  Hungria VTM, Latrilha MC, Rodrigues DG, Bydlowsky SP, 
Chiattone CS, Maranhao RC. Metabolism of a cholesterol-rich micro-
emulsion (LDE) in patients with multiple myeloma and preliminary 
clinical study of LDE as drug vehicle for the treatment of the disease. 
Cancer Chemother Pharmacol. 2004;53:51–60.
  22.  Rodrigues DG, Maria DA, Fernandes DC, et al. Improvement of 
paclitaxel therapeutic index by derivatization and association to a 
cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer 
Chemother Pharmacol. 2005;55:565–576.
  23.  Valduga CJ, Fernandes DC, Lo Prete AC, Azevedo CHM, Rodrigues DG, 
Maranhao RC. Use of a cholesterol-rich microemulsion that binds to 
low-density lipoprotein receptors as vehicle for etoposide. J Pharm 
Pharmacol. 2003;55:1615–1622.
  24.  Lo Prete AC, Maria DA, Rodrigues DG, Valduga CJ, Ibañez OC, 
Maranhão RC. Evaluation in melanoma-bearing mice of an etoposide 
derivative associated to a cholesterol-rich nano-emulsion. J Pharm 
Pharmacol. 2006;58:801–808.
  25.  Ades A, Carvalho, JP, Graziani, SR, et al. Uptake of a cholesterol-
rich emulsion by neoplastic ovarian tissues. Gynecol Oncol. 
2001;81:84–87.
  26.  Graziani SR, Igreja FAF, Hegg R, et al. Uptake of a cholesterol-rich 
emulsion by breast cancer. Gynecol Oncol. 2002;85:493–497.
  27.  Azevedo CH, Carvalho JP, Valduga CJ, Maranhão RC. Plasma kinetics 
and uptake by the tumor of a cholesterol-rich microemulsion (LDE) 
associated to etoposide oleate in patients with ovarian carcinoma. 
Gynecol Oncol. 2005;97:178–182.
  28.  Dias ML,Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC. 
Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel 
associated to a cholesterol-rich nanoemulsion (LDE) in patients with gyne-
cologic cancers. Cancer Chemother Pharmacol. 2007;59:105–111.
  29.  Pinheiro KV, Hungria VT, Ficker ES, Valduga CJ, Mesquita CH, 
Maranhao RC. Plasma kinetics of a cholesterol-rich microemulsion 
(LDE) in patients with Hodgkin’s lymphoma and a preliminary study 
on the toxicity of etoposide associated with LDE. Cancer Chemother 
Pharmacol. 2006;57:624–630.
  30.  Rosowsky A, Forsch RA, Yu CS, Lazarus H, Beardsley GP. Methotrexate 
analogues. 21. Divergent influence of alkyl chain on the dihydrofolate 
reductase affinity and cytotoxicity of methotrexate monoesters. J Med 
Chem. 1984;27:605–609.
  31.  Mosmann T. Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assay. J Immunol Methods. 
1983;65:55–63.
  32.  Lowry OH, Rosebrough NJ, Farr AL, Randall R. Protein measurement 
with the Folin phenol reagent. J Biol Chem. 1951;193:265–275.
  33.  Saito H, Kawagishi A, Tanaka M, et al. Coalescence of lipid emulsions 
in floating and freeze-thawing processes: examination of the coalescence 
transition state theory. J Colloid Interface Sci. 1999;219:129–134.
  34.  Kabalnov A, Tarara T, Arlauskas R, Werrs J. Phospholipids as emul-
sion stabilizers. 2. Phase behavior versus emulsion stability. J Colloid 
Interface Sci. 1996;184:227–235.
  35.  Pignatello R, Spampinato G, Sorrenti V, et al. Lipophilic metho-
trexate conjugates with antitumor activity. Eur J Pharm Sci. 
2000;10:237–245.
  36.  Maranhão RC, Tavares ER, Padoveze AF, Valduga CJ, Rodrigues DG, 
Pereira MD. Paclitaxel associated with cholesterol-rich nanoemulsions 
promotes atherosclerosis regression in the rabbit. Atherosclerosis. 
2008;197:959–966.
  37.  Ofner CM 3rd, Pica K, Bowman BJ, Chen CS. Growth inhibition, drug 
load, and degradation studies of gelatin/methotrexate conjugates. Int J 
Pharm. 2006;308:90–99.